JP2019521154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521154A5 JP2019521154A5 JP2019501917A JP2019501917A JP2019521154A5 JP 2019521154 A5 JP2019521154 A5 JP 2019521154A5 JP 2019501917 A JP2019501917 A JP 2019501917A JP 2019501917 A JP2019501917 A JP 2019501917A JP 2019521154 A5 JP2019521154 A5 JP 2019521154A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- tumor
- dna molecule
- cell clone
- transformed cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 41
- 102000036639 antigens Human genes 0.000 claims 40
- 108091007433 antigens Proteins 0.000 claims 40
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 108020004414 DNA Proteins 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 102000053602 DNA Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 10
- 108010041986 DNA Vaccines Proteins 0.000 claims 6
- 229940021995 DNA vaccine Drugs 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000607142 Salmonella Species 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 238000002619 cancer immunotherapy Methods 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 229920001817 Agar Polymers 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000008272 agar Substances 0.000 claims 2
- 239000000356 contaminant Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241001467018 Typhis Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022074854A JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550.9 | 2016-07-13 | ||
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074854A Division JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521154A JP2019521154A (ja) | 2019-07-25 |
| JP2019521154A5 true JP2019521154A5 (enExample) | 2020-08-20 |
| JP7098599B2 JP7098599B2 (ja) | 2022-07-11 |
Family
ID=56418345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501917A Active JP7098599B2 (ja) | 2016-07-13 | 2017-07-12 | 癌免疫療法用のｄｎａワクチンの製造方法 |
| JP2022074854A Pending JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074854A Pending JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (enExample) |
| EP (1) | EP3484503A1 (enExample) |
| JP (2) | JP7098599B2 (enExample) |
| KR (2) | KR20190027834A (enExample) |
| CN (1) | CN109475614A (enExample) |
| AU (1) | AU2017295004B2 (enExample) |
| BR (1) | BR112019000657A2 (enExample) |
| CA (1) | CA3028549A1 (enExample) |
| IL (1) | IL263568A (enExample) |
| MX (1) | MX2019000415A (enExample) |
| RU (1) | RU2019100079A (enExample) |
| SG (1) | SG11201811258UA (enExample) |
| WO (1) | WO2018011289A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019009724A (es) * | 2017-02-17 | 2019-10-07 | Vaximm Ag | Nueva estrategia de inmunoterapia dirigida al vegfr-2. |
| CA3069523A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| WO2020049036A1 (en) | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2023510770A (ja) | 2020-01-13 | 2023-03-15 | バクシム アクチェンゲゼルシャフト | 抗生剤と組み合わせた、サルモネラベースのｄｎａワクチン |
| US20250340919A1 (en) * | 2022-06-30 | 2025-11-06 | Shimadzu Corporation | Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2746233T3 (es) * | 2011-05-24 | 2020-03-05 | Biontech Rna Pharmaceuticals Gmbh | Vacunas individualizadas para el cáncer |
| DK2794849T3 (da) * | 2011-12-22 | 2017-11-06 | Vaximm Ag | Fremgangsmåde til fremstilling af svækkede salmonellastammer med højt udbytte |
| DK2869836T3 (da) * | 2012-07-05 | 2019-11-25 | Vaximm Ag | Dna-vaccine til anvendelse hos patienter med pankreascancer |
| EP2988762B1 (en) * | 2013-04-25 | 2018-06-06 | Vaximm AG | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| LT3082850T (lt) | 2013-12-18 | 2019-11-11 | Vaximm Gmbh | Į msln nukreipta dnr vakcina vėžio imunoterapijai |
| BR112016014410A2 (pt) * | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
-
2017
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521154A5 (enExample) | ||
| RU2019100079A (ru) | Способ получения днк-вакцины для иммунотерапии рака | |
| IL299249B1 (en) | Genetically modified immune cells that include adapted shrna-microRNA (shrnamir) | |
| CN113711239A (zh) | 利用ii类mhc模型鉴别新抗原 | |
| Fredericks et al. | The species-specific acquisition and diversification of a K1-like family of killer toxins in budding yeasts of the Saccharomycotina | |
| Bolinger et al. | Adenoviral vector vaccination induces a conserved program of CD8+ T cell memory differentiation in mouse and man | |
| CN111868080A (zh) | 利用泛等位基因模型进行的新抗原鉴别 | |
| CN111465989A (zh) | 使用热点进行的新抗原鉴别 | |
| JP2019510465A5 (enExample) | ||
| JP2018511321A5 (enExample) | ||
| CN104560864A (zh) | 利用CRISPR-Cas9系统构建的敲除IFN-β基因的293T细胞系 | |
| CN112080521B (zh) | 一种表达外源蛋白的重组伪狂犬病毒载体构建及重组伪狂犬病毒制备方法 | |
| CN105331635A (zh) | 一种诱导型慢病毒表达体系及其构建方法和应用 | |
| Malouli et al. | Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species | |
| WO2020124830A1 (zh) | 基于人工串联启动子的枯草芽孢杆菌高效诱导表达系统 | |
| JP2019511218A5 (enExample) | ||
| CN105132350B (zh) | 一种减毒鼠伤寒沙门氏菌的构建方法及其所得菌株和应用 | |
| Pfenninger et al. | Naïve primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering | |
| Kistler et al. | Structural dynamics of Fusarium genomes | |
| JP2015507472A5 (enExample) | ||
| CN105879060B (zh) | 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗 | |
| Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
| EP3159411B1 (en) | Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof | |
| CN109758590B (zh) | 一种用于筛选人前列腺癌肿瘤抗原表位肽的方法 | |
| CN113423724B (zh) | Ebv表位高亲和力t细胞受体 |